These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11256 related articles for article (PubMed ID: 10685653)

  • 41. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
    Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Our experience with interferon alpha: metastatic malignant melanoma.
    Merimsky O; Chaitchik S
    Mol Biother; 1992 Sep; 4(3):135-8. PubMed ID: 1445667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
    Harting MS; Kim KB
    Melanoma Res; 2004 Dec; 14(6):517-20. PubMed ID: 15577323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
    Anderson CM; Buzaid AC; Sussman J; Lee JJ; Ali-Osman F; Braunschweiger PG; Plager C; Bedikian A; Papadopoulos N; Eton O; Legha SS; Grimm EA
    Melanoma Res; 1998 Apr; 8(2):149-55. PubMed ID: 9610868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
    Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
    Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
    O'Day SJ; Gammon G; Boasberg PD; Martin MA; Kristedja TS; Guo M; Stern S; Edwards S; Fournier P; Weisberg M; Cannon M; Fawzy NW; Johnson TD; Essner R; Foshag LJ; Morton DL
    J Clin Oncol; 1999 Sep; 17(9):2752-61. PubMed ID: 10561350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
    Buzaid AC; Grimm EA; Ali-Osman F; Ring S; Eton O; Papadopoulos NE; Bedikian A; Plager C; Legha SS; Benjamin R
    Melanoma Res; 1994 Oct; 4(5):327-30. PubMed ID: 7858418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V; Herrmann R; Veelken H; Schwabe M
    Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
    Buzaid AC; Colome M; Bedikian A; Eton O; Legha SS; Papadopoulos N; Plager C; Ross M; Lee JE; Mansfield P; Rice J; Ring S; Lee JJ; Strom E; Benjamin R
    Melanoma Res; 1998 Dec; 8(6):549-56. PubMed ID: 9918417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of metastatic cutaneous melanoma.
    Buzaid AC
    Oncology (Williston Park); 2004 Oct; 18(11):1443-50; discussion 1457-9. PubMed ID: 15609471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature.
    Castro MP; VanAuken J; Spencer-Cisek P; Legha S; Sponzo RW
    Cancer; 1999 Mar; 85(5):1055-9. PubMed ID: 10091788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemotherapy in patients with metastatic anorectal mucosal melanoma.
    Kim KB; Sanguino AM; Hodges C; Papadopoulos NE; Eton O; Camacho LH; Broemeling LD; Johnson MM; Ballo MT; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Prieto VG; Bedikian AY
    Cancer; 2004 Apr; 100(7):1478-83. PubMed ID: 15042682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen.
    Reintgen D; Saba H
    Semin Surg Oncol; 1993; 9(3):251-5. PubMed ID: 8516613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
    Bajetta E; Del Vecchio M; Nova P; Fusi A; Daponte A; Sertoli MR; Queirolo P; Taveggia P; Bernengo MG; Legha SS; Formisano B; Cascinelli N
    Ann Oncol; 2006 Apr; 17(4):571-7. PubMed ID: 16469753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
    Minor DR; Madland MT; Kashani-Sabet M; Denny SR; Harvey WB
    Cancer Biother Radiopharm; 2005 Oct; 20(5):479-86. PubMed ID: 16248763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
    Grimm EA; Smid CM; Lee JJ; Tseng CH; Eton O; Buzaid AC
    Clin Cancer Res; 2000 Oct; 6(10):3895-903. PubMed ID: 11051235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 563.